Explore
Trendline
Kahn Swick Foti Investigates Catalyst Pharmaceuticals Sale for Fairness
Kahn Swick Foti Investigates Catalyst Pharmaceuticals Sale for Fairness
Read More
Trendline
Scotts Miracle-Gro Faces Legal Investigation Following Stock Decline
Scotts Miracle-Gro Faces Legal Investigation Following Stock Decline
Read More
Trendline
Law Firm Investigates Scotts Miracle-Gro Following Stock Decline Due to Poor Financial Results
Law Firm Investigates Scotts Miracle-Gro Following Stock Decline Due to Poor Financial Results
Read More
Trendline
Scotts Miracle-Gro Faces Legal Scrutiny Following Stock Decline
Scotts Miracle-Gro Faces Legal Scrutiny Following Stock Decline
Read More
Trendline
Scotts Miracle-Gro Faces Legal Scrutiny After Stock Plunge
Scotts Miracle-Gro Faces Legal Scrutiny After Stock Plunge
Read More
Trendline
Kahn Swick Foti, LLC Initiates Investigation into Scotts Miracle-Gro Over Financial Disclosures
Kahn Swick Foti, LLC Initiates Investigation into Scotts Miracle-Gro Over Financial Disclosures
Read More
Trendline
Robbins LLP Files Class Action Against Graphic Packaging Holding Company Over Alleged Misleading Practices
Robbins LLP Files Class Action Against Graphic Packaging Holding Company Over Alleged Misleading Practices
Read More
Trendline
Rosen Law Firm Urges Gartner Stockholders to Join Class Action Lawsuit
Rosen Law Firm Urges Gartner Stockholders to Join Class Action Lawsuit
Read More
Trendline
Private Equity Firms Invest Heavily in AI Data Centers Amid $900 Billion Opportunity
Private Equity Firms Invest Heavily in AI Data Centers Amid $900 Billion Opportunity
Read More
Trendline
Southeastern Asset Management Urges Mattel to Go Private Amid Stock Decline
Southeastern Asset Management Urges Mattel to Go Private Amid Stock Decline
Read More
Trendline
Kirby McInerney LLP Investigates Azenta, Inc. for Potential Securities Fraud Following Financial Disclosures
Kirby McInerney LLP Investigates Azenta, Inc. for Potential Securities Fraud Following Financial Disclosures
Read More
Trendline
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1B to Enter U.S. Rare Disease Market
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1B to Enter U.S. Rare Disease Market
Read More